Acrivon Therapeutics, Inc. Common Stock·Healthcare
Acrivon Therapeutics (NASDAQ: ACRV - Get Free Report) and Oasmia Pharmaceutical (OTCMKTS:OASMY - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends. Valuation and Earnings This table compares Acrivon
Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC)
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs)
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acrivon Therapeutics (NASDAQ: ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company's ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, with particular attention on results in serous endometrial cancer. The panel discussion followed a late-breaking presentation at a major oncology meeting by Dana-Farber's Panagiotis Konstantinopoulos, with data reviewed on
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D.
